NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) An
Post# of 158
(Total Views: 107)
Posted On: 09/16/2024 4:53:25 PM
NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, will be meeting in-person with the U.S. Food and Drug Administration (“FDA”) before the end of November 2024. The company announced that the meeting, which will focus on discussions about the development of the company’s proprietary CNM-Au8 for the treatment of amyotrophic lateral sclerosis (“ALS”), will include key FDA representatives, including the organization’s director of the Office on New Drugs and director of the Office of Neuroscience, as well as the Division of Neurology 1 (“DN1”) review team and key opinion leaders in the ALS, biostatistics and biomarkers space.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, will be meeting in-person with the U.S. Food and Drug Administration (“FDA”) before the end of November 2024. The company announced that the meeting, which will focus on discussions about the development of the company’s proprietary CNM-Au8 for the treatment of amyotrophic lateral sclerosis (“ALS”), will include key FDA representatives, including the organization’s director of the Office on New Drugs and director of the Office of Neuroscience, as well as the Division of Neurology 1 (“DN1”) review team and key opinion leaders in the ALS, biostatistics and biomarkers space.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)